$2.80
+0.31 (+12.45%)
Open$2.53
Previous Close$2.49
Day High$2.88
Day Low$2.48
52W High$3.23
52W Low$0.93
Volume—
Avg Volume2.56M
Market Cap293.73M
P/E Ratio—
EPS$-1.09
SectorBiotechnology
Analyst Ratings
Buy
18 analysts
Price Target
+105.4% upside
Current
$2.80
$2.80
Target
$5.75
$5.75
$4.43
$5.75 avg
$6.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.86M | 14.30M | 39.14M |
| Net Income | -120,376,503 | -264,112,268 | -10,010,485 |
| Profit Margin | -2,051.1% | -1,948.5% | -25.6% |
| EBITDA | -119,044,232 | -275,699,708 | -16,322,152 |
| Free Cash Flow | — | — | -10,981,777 |
| Rev Growth | -59.0% | -59.0% | +22.5% |
| Debt/Equity | 0.05 | 0.05 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |